Technology & Innovation

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics has signed a new manufacturing agreement with AAVantgarde Bio to produce dual-vector AAV gene therapies for Stargardt disease and retinitis pigmentosa, positioning its BravoAAV™ platform at the center of next-generation treatments for inherited retinal disorders with no approved therapies.

Dual-vector AAV platform targets previously "untreatable" retinal genes

Under the deal, AGC Biologics will provide GMP manufacturing for AAVantgarde's two clinical-stage candidates: AAVB-039 for Stargardt disease, the most common inherited form of macular degeneration in children and young adults, and AAVB-081 for retinitis pigmentosa caused by Usher syndrome type 1B. Both programs are in Phase 1/2 trials, with AAVB-039 being tested in the U.S., UK and Europe, and AAVB-081 representing the first-ever dual AAV gene therapy in an ocular indication.

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics has signed a strategic development and manufacturing agreement with Repair Biotechnologies to advance a novel mRNA therapeutic aimed at rapidly stabilizing and shrinking atherosclerotic plaques, addressing what both partners describe as the leading single cause of human mortality worldwide.

Targeting plaque biology in a high-burden cardiovascular market

The collaboration focuses on an mRNA-based therapy designed to stabilize and reduce atherosclerotic plaques in major blood vessels, directly tackling the root pathology behind heart attacks and strokes. Rupture of unstable plaque and subsequent thrombotic events account for an estimated 27% of all human deaths, underscoring the strategic importance of any technology capable of reversing or halting plaque progression.

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics is partnering with public benefit company Rarity PBC to bring a potentially life-saving gene therapy for Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) through commercial manufacturing and toward FDA approval, underscoring how CDMO collaborations are becoming central to translating academic breakthroughs into scalable rare disease treatments.

From transformational trials to a U.S. commercial pathway

Under the new agreement, AGC Biologics will provide end-to-end development and GMP manufacturing for Rarity's ex vivo autologous gene therapy RDP-101. If approved, RDP-101 would become the first gene therapy commercially available in the United States to reverse ADA-SCID, a rare inherited immunodeficiency that leaves infants dangerously exposed to severe, recurrent infections.

SHERIDAN, WYOMING - December 2, 2025 - Ricoh has introduced its new IM Cxx01CE A3 color multifunction series, positioning the IM C2501CE, IM C3501CE and IM C5501CE as a new sustainability benchmark for office print fleets by combining high reuse rates, lower CO₂ footprint and upgraded security with cloud-ready workflows.

Circular-economy design with high reuse and lower CO₂ footprint

Developed explicitly with circular-economy principles in mind, the new IM Cxx01CE models are manufactured using over 86% reused components and deliver a CO₂ footprint reduced by around 50% compared to comparable multifunction systems. By building on existing hardware resources and refreshing them with the latest security and performance elements, Ricoh enables customers to pursue sustainability targets while maintaining familiar functionality and reliability.

SHERIDAN, WYOMING - December 2, 2025 - Ricoh and Neat have signed a global partnership agreement to deliver integrated, high-end audiovisual solutions for modern workplaces worldwide, combining Neat's AI-driven video devices with Ricoh's AV Managed Services to enhance hybrid collaboration and workplace experience.

Master-level alliance to scale premium meeting experiences

Under the agreement, Neat, a global leader in professional AV and innovative video technology, and Ricoh, a global leading AV integrator, will collaborate at the highest tier of Neat's Global Partner Program-the Mastery level. The partnership is designed to expand Ricoh's portfolio of high-end meeting room solutions and make Neat-powered spaces more accessible across enterprises of all sizes.

SHERIDAN, WYOMING - December 2, 2025 - More than 3,000 print service providers worldwide are now using the cloud-based HEIDELBERG Customer Portal as a digital control center for their end-to-end production, underscoring how system integration and workflow automation are becoming decisive competitive factors in the global print and packaging industry.

Cloud platform becomes a digital command center for print plants

Three years after launch, Heidelberger Druckmaschinen AG's (HEIDELBERG) customer portal is evolving into a central hub for managing production, service and commercial processes. Over 7,000 individual users are actively leveraging the platform to digitalize and automate their operations, with a clear focus on improving efficiency, transparency and sustainability.

SHERIDAN, WYOMING - December 2, 2025 - Swiss communications provider rubmedia has commissioned a compact, highly automated Heidelberg digital print line at its new site in Köniz near Bern, combining a Jetfire 50 inkjet system, a Versafire LV toner press and integrated workflow software to industrialize personalized short-run production.

Digital production line anchors new Köniz facility

With around 35 employees, rubmedia positions itself as a media house focused on creative communication solutions for service providers, industry, associations and political customers. As part of an internal transformation project linked to its relocation, the company rethought its production strategy and installed a tightly integrated digital line designed for efficiency, quality and automation.

SHERIDAN, WYOMING - December 2, 2025 - Roche has reported landmark Phase III results for its oral selective estrogen receptor degrader (SERD) giredestrant, positioning the candidate as a potential new standard of care in early-stage ER-positive, HER2-negative breast cancer after a pivotal trial showed superior invasive disease-free survival versus standard endocrine therapy.

First oral SERD to show superior invasive disease-free survival

The Phase III lidERA Breast Cancer study evaluated adjuvant giredestrant against standard-of-care endocrine monotherapy in more than 4,100 patients with medium- or high-risk stage I-III ER-positive, HER2-negative early breast cancer. At a pre-planned interim analysis, the trial met its primary endpoint: giredestrant delivered a statistically significant and clinically meaningful improvement in invasive disease-free survival compared with standard endocrine therapy.

SHERIDAN, WYOMING - December 2, 2025 - Roche is re-entering the frontline of Alzheimer's disease drug development, after new Phase I/II data showed its next-generation antibody trontinemab cleared amyloid plaques below the threshold of positivity in the vast majority of treated patients while keeping key safety signals under tight control.

Early Brainshuttle data show deep amyloid clearance

In the ongoing Brainshuttle AD Phase I/II study, 92% of patients treated with trontinemab achieved amyloid levels below 24 centiloids, the PET scan threshold commonly used to define amyloid positivity. The data, presented at the 2025 Clinical Trials on Alzheimer's Disease (CTAD) meeting, mark one of the strongest plaque-clearing signals yet seen in a mid-stage program.

SHERIDAN, WYOMING - December 2, 2025 - Imvax is moving its autologous glioblastoma immunotherapy IGV-001 toward the FDA, despite a missed primary endpoint in Phase IIb, betting that a six-month overall survival benefit and a novel "synergistic" treatment concept will resonate in a setting where outcomes have barely budged in two decades.

Phase IIb data highlight survival benefit despite PFS miss

In a mid-stage trial of 99 patients with newly diagnosed glioblastoma, Imvax evaluated IGV-001, a biologic-device combination, against placebo. While the study did not achieve its primary endpoint of improving progression-free survival, the company reported a median overall survival of 20.3 months in the treatment arm-around six months longer than in the control group.